PhenoVision Secures Tens of Millions in Angel Funding to Accelerate Clinical Commercialization of Spatial Multi-Omics

Recently, Beijing Fenuoweikang Biotechnology Co., Ltd. (hereinafter referred to as “Fenuoweikang”) announced the completion of an angel financing round amounting to tens of millions of yuan, exclusively invested by Yuanhe Origin. The proceeds from this round will be primarily used for the establishment of Fenuoweikang’s spatial multi-omics technology platform and the application development of clinical products.

In recent years, life science technologies have undergone a leap from tissue homogenization to the single-cell dimension, enabling researchers to obtain genomic, transcriptomic, epigenetic, and proteomic information from individual cells. Although technical strategies such as bulk sample analysis or single-cell sequencing can generate massive amounts of biological data, they fail to capture critical information regarding cellular spatial distribution and interactions. With the advent of the era of spatial multi-omics, there is an increasingly clear demand for more comprehensive studies of multi-level biological pathways, a deeper understanding of complex diseases, and related clinical applications. Spatial multi-omics simultaneously meets the needs for single-cell resolution, quantitative data, and multidimensional analysis of the spatial microenvironment, helping to address complex biological questions and providing higher-dimensional biological insights and solutions for the diagnosis and treatment of complex diseases.

The international market for spatial multi-omics is heating up, with publicly listed companies entering the fray and emerging startups flourishing. AKOYA Bioscience, which went public in 2021, rapidly established a strategic partnership with Bio-Techne this January to expand its presence in spatial multi-omics. 10x Genomics has also made a strong entry into the spatial multi-omics arena by spending heavily to acquire Cartana and ReadCoor, a spatial multi-omics platform. Recently, Vizgen, a spatial multi-omics company, announced the completion of an $85.2 million Series C financing round, bringing its total funding to $136 million. Evidently, the spatial era has arrived, and the spatial multi-omics sector holds immense commercial opportunities.

Beijing Fenuoweikang Biotechnology Co., Ltd., headquartered in Beijing, is dedicated to creating one-stop spatial multi-omics solutions for diverse application scenarios. Founder Li Yang graduated from Peking Union Medical College and brings nearly 20 years of industry experience and resources in pathological diagnosis, spatial transcriptomics, and spatial proteomics. He previously worked in the Pathology Division of Roche Diagnostics, and later served as General Manager for Greater China at Advanced Cell Diagnostics, a leading company in spatial transcriptomics, and as Director of Business Development for Asia-Pacific at Akoya Bioscience, a representative firm in spatial biology technologies. He possesses extensive experience in spatial multi-omics product development, clinical translation, and commercial promotion. Core team members also have over ten years of experience in building technical platforms, developing products, and implementing clinical applications in the field of spatial multi-omics.

Spatial multi-omics plays a crucial role in the research and application of complex diseases, including neurological disorders, tumors, and developmental conditions. Driven by breakthroughs and maturation in spatial proteomics, spatial transcriptomics, and single-cell sequencing technologies, the clinical translation of spatial multi-omics has reached a turning point, paving the way for greater precision in clinical pathology. However, achieving multi-omic analysis within the same tissue sample has long been a challenging issue in clinical medicine. Currently, domestic platforms in China are constrained by technological limitations, allowing only for either RNA or protein assays.

By combining the introduction of advanced international technologies with independent research and development, Fenuoweikang is committed to creating China’s only solution capable of simultaneously capturing spatial multi-omics (DNA/RNA/protein) information on a single platform. This solution includes reagents for spatial multi-omics detection, automated equipment, and software capable of interpreting DNA, RNA, and protein bioinformation, with the goal of providing clinically accessible applications.

Founder Li Yang stated: Spatial multi-omics technologies are transforming our understanding of complex diseases by providing precise spatial coordinates for cells and molecules. Over the past 20 years of my professional career, I have been deeply involved in the technological development and translational advancement of spatial transcriptomics and spatial proteomics. I believe that now is the optimal time for spatial multi-omics to enter clinical applications, with spatially resolved pathological visualization serving as the key entry point for clinical implementation. After years of preparation and accumulation, the founding team of Beijing Fenuoweikang Biotechnology Co., Ltd. and I are honored to partner with Yuanhe Yuandian to jointly promote the application and development of spatial multi-omics technologies in areas such as disease diagnosis, cancer treatment, and new drug research and development, thereby bringing about revolutionary changes in cancer diagnosis and therapy.

Dr. Hu Xiaofang, Partner at Yuanhe Origin, stated: Life processes are driven by intricate and complex changes occurring across multiple patterns simultaneously. Spatial multi-omics integrates precise multi-omics quantification with spatial information, elevating our understanding of biological data to new heights, which is crucial for comprehending the essence of life. With advancements in single-cell technologies and the expansion of analytical tools, spatial multi-omics has reached a tipping point for application and industrial commercialization, becoming a key instrument for future precision medicine. Having known founder Li Yang for many years, we recognize his accumulated expertise and competitive advantages in the spatial multi-omics sector, and we are well aware of the technical strength and translational capabilities of Beijing Fenuoweikang Biotechnology Co., Ltd.’s founding team. We look forward to collaborating with Beijing Fenuoweikang Biotechnology Co., Ltd. to jointly accelerate the clinical implementation and application of spatial multi-omics.

Yuanhe Origin is a specialized early-stage equity investment platform under Yuanhe Holdings, operating on a market-oriented basis. It focuses primarily on investment opportunities in start-ups and early-growth enterprises within the technology and healthcare sectors. With a total fund size of approximately RMB 5 billion, it manages both venture capital (VC) funds and regionally targeted angel funds, committed to empowering entrepreneurial ventures with growth momentum and growing alongside founders.